Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges

Journal of Law, Medicine and Ethics 38 (2):277-285 (2010)
Abstract
This paper discusses exceptional circumstances under which patients outside of clinical trials are likely to receive innovative stem cell-based interventions. These circumstances involve: (1) stem cell interventions not initially amenable to a clinical trials approach; (2) expanded access to investigational stem cell products (“compassionate use”); and (3) off-label uses of FDA approved stem cell products. This paper proposes a new approach to regulating these exceptional cases
Keywords No keywords specified (fix it)
Categories (categorize this paper)
Options
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history Request removal from index
 
Download options
PhilPapers Archive


Upload a copy of this paper     Check publisher's policy on self-archival     Papers currently archived: 10,724
External links
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library
References found in this work BETA
George J. Agich (2001). Ethics and Innovation in Medicine. Journal of Medical Ethics 27 (5):295-296.
Citations of this work BETA
John A. Robertson (2010). Embryo Stem Cell Research: Ten Years of Controversy. Journal of Law, Medicine and Ethics 38 (2):191-203.
John A. Robertson (2010). Introduction. Journal of Law, Medicine and Ethics 38 (2):175-190.
Similar books and articles
Analytics

Monthly downloads

Added to index

2010-08-11

Total downloads

6 ( #201,648 of 1,098,601 )

Recent downloads (6 months)

1 ( #285,544 of 1,098,601 )

How can I increase my downloads?

My notes
Sign in to use this feature


Discussion
Start a new thread
Order:
There  are no threads in this forum
Nothing in this forum yet.